

Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371311-00009	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Temozolomide Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom
	Telephone	:	+44 (0) 2081548000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 2 Eye irritation, Category 2 Germ cell mutagenicity, Category 2 Carcinogenicity, Category 2 Reproductive toxicity, Category 1B

Specific target organ toxicity - repeated exposure, Category 1

H300: Fatal if swallowed.
H319: Causes serious eye irritation.
H341: Suspected of causing genetic defects.
H351: Suspected of causing cancer.
H360FD: May damage fertility. May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		SDS Number: 9371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Haza	rd pictograms	:		
Signa	al word	:	Danger	•
Haza	rd statements	:	H319 Caus H341 Susp H351 Susp H360FD May child H372 Caus	l if swallowed. ses serious eye irritation. bected of causing genetic defects. bected of causing cancer. damage fertility. May damage the unborn l. ses damage to organs through prolonged or ated exposure.
Preca	autionary statements	:	P260 Do r P280 Wea	ain special instructions before use. not breathe dust. Ir protective gloves/ protective clothing/ eye ection/ face protection.
			P308 + P313 IF atter P337 + P313 If	 330 IF SWALLOWED: Immediately call a SON CENTER/ doctor. Rinse mouth. exposed or concerned: Get medical advice/ ntion. eye irritation persists: Get medical advice/ ntion.

Hazardous components which must be listed on the label: Temozolomide

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Temozolomide	85622-93-1	Acute Tox. 2; H300 Muta. 2; H341 Carc. 2; H351	>= 50 - < 70

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Temozolomide Formulation

ersion .4	Revision Date: 28.09.2024	SDS Number: 9371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
			Repr. 1B; H360FD STOT RE 1; H372 (Bone marrow, thymus gland, Lymph nodes, spleen)	
(+)-Ta	artaric acid	87-69-4 201-766-0	Eye Dam. 1; H318	>= 1 - < 3

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures General advice In the case of accident or if you feel unwell, seek medical ad-: vice immediately. When symptoms persist or in all cases of doubt seek medical advice. Protection of first-aiders First Aid responders should pay attention to self-protection, : and use the recommended personal protective equipment when the potential for exposure exists (see section 8). If inhaled If inhaled, remove to fresh air. : Get medical attention. In case of skin contact In case of contact, immediately flush skin with soap and plenty : of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of eye contact In case of contact, immediately flush eyes with plenty of water : for at least 15 minutes. If easy to do, remove contact lens, if worn, Get medical attention. If swallowed If swallowed, DO NOT induce vomiting. : Call a physician or poison control centre immediately. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. 4.2 Most important symptoms and effects, both acute and delayed Risks Fatal if swallowed. • Causes serious eye irritation. Suspected of causing genetic defects. Suspected of causing cancer.

exposure.

May damage fertility. May damage the unborn child. Causes damage to organs through prolonged or repeated

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371311-00009	Date of first issue: 27.08.2021

Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

5.2 Special hazards arising from the substance or mixture

5.2 Special nazarus ansing	monn the	
Specific hazards during f fighting	ire- :	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion p ucts	orod- :	Carbon oxides Nitrogen oxides (NOx) Metal oxides
5.3 Advice for firefighters		
Special protective equipr for firefighters	ment :	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing me ods	eth- :	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro-
	tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avo

: Avoid release to the environment.



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		Retain and disp If spillage enter	leakage or spillage if safe to do so. bose of contaminated wash water. 's rivers or watercourses, inform the Environ- emergency telephone number 0800 807060).
6.3 Metho	ds and material for c	ontainment and clea	ning up
Methods for cleaning up :		tainer for dispos Avoid dispersal with compresse Dust deposits s es, as these ma leased into the Local or nationa posal of this ma employed in the mine which reg Sections 13 and	of dust in the air (i.e., clearing dust surfaces

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the
Hygiene measures	:	environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		The effective engineering of appropriate d industrial hyg	g before re-use. operation of a facility should include review of controls, proper personal protective equipment, legowning and decontamination procedures, iene monitoring, medical surveillance and the istrative controls.
7.2 Condi	tions for safe storage,	, including any inc	compatibilities
	irements for storage and containers		erly labelled containers. Store locked up. Keep . Store in accordance with the particular national
Advic	e on common storage	Strong oxidiz Self-reactive Organic pero Flammable li Flammable s Pyrophoric lid Pyrophoric so Self-heating s	substances and mixtures xides quids olids quids blids substances and mixtures and mixtures, which in contact with water, emit
7.3 Specif	ic end use(s)		
Speci	fic use(s)	: No data avail	able
		No data avail	able

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind	10 mg/m3 Value type (Form of exposure): TWA (Inhalable) Basis: GB EH40
	4 mg/m3 Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

Derived No Effect Level (DNEL)





Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		SDS Number:Date of last issue: 06.04.20249371311-00009Date of first issue: 27.08.2021		
Subs	stance name	End Use	Exposure routes	Potential health ef- fects	Value
(+)-T	artaric acid	Workers	Inhalation	Long-term systemic effects	5.2 mg/m3
		Workers	Skin contact	Long-term systemic effects	2.9 mg/kg bw/day
		Consumers	Inhalation	Long-term systemic effects	1.3 mg/m3
		Consumers	Skin contact	Long-term systemic effects	1.5 mg/kg bw/day
		Consumers	Ingestion	Long-term systemic effects	8.1 mg/kg bw/day
Stear	ric acid	Workers	Inhalation	Long-term systemic effects	17.63 mg/m3
		Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
		Consumers	Inhalation	Long-term systemic effects	4.348 mg/m3
		Consumers	Skin contact	Long-term systemic effects	5 mg/kg bw/day
		Consumers	Ingestion	Long-term systemic effects	2.5 mg/kg bw/day

Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value
(+)-Tartaric acid	Fresh water	0.3125 mg/l
	Freshwater - intermittent	0.514 mg/l
	Marine water	0.3125 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1.141 mg/kg dry weight (d.w.)
	Marine sediment	1.141 mg/kg dry weight (d.w.)
	Soil	0.0449 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

:

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021			
potential for direct aerosols. Hand protection		•	lirect contact to the face with dusts, mists, or			
Ma	aterial	: Chemical-resi	: Chemical-resistant gloves			
Remarks Skin and body protection		: Work uniform Additional boo being perform suits) to avoic Use appropria	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.			
Respiratory protection :		: If adequate lo sure assessm ommended g	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143			
Fil	/pe (P)					

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour	:	powder off-white
Odour	:	No data available
Odour Threshold	÷	No data available
	-	
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available



Temozolomide Formulation

Vers 4.4	sion	Revision Date: 28.09.2024		S Number: 71311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
	Density	y	:	1 g/cm³	
Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature		::	No data available No data available No data available	9 9	
Decomposition temperature		:	No data available	9	
	Viscos Vise	ity cosity, kinematic	:	No data available	9
Explosive properties		:	Not explosive		
Oxidizing properties		:	The substance o	r mixture is not classified as oxidizing.	
9.2 (nformation ability (liquids)	:	No data available	e
	Molecu	ılar weight	:	No data available	9
	Particle	e size	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	 May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371311-00009	Date of first issue: 27.08.2021

SECTION 11: Toxicological information

11.1 Information on toxicological effects				
Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact		
Acute toxicity				
Fatal if swallowed.				
Product:				
Acute oral toxicity	:	Acute toxicity estimate: 33.93 mg/kg Method: Calculation method		
Components:				
Temozolomide:				
Acute oral toxicity	:	LD50 (Dog): 19 mg/kg		
		LD50 (Rat): 315 mg/kg		
		LD50 (Mouse): 205 mg/kg		
(+)-Tartaric acid:				
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423		
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity		

Skin corrosion/irritation

Not classified based on available information.

Components:

(+)-Tartaric acid:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

(+)-Tartaric acid:

Species

: Bovine cornea

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		OS Number: 71311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Met	hod	:	OECD Test Guid	eline 437
Res	ult	:	Irreversible effect	s on the eye
Res	piratory or skin sensiti	satio	on	
-	n sensitisation classified based on avail	lable	information.	
	piratory sensitisation classified based on avail	lable	information.	
<u>Con</u>	nponents:			
Tes Exp	n ozolomide: t Type osure routes cies sult		Maximisation Tes Dermal Guinea pig negative	it
(+)-	Tartaric acid:			
Exp		: :	Local lymph node Skin contact Mouse OECD Test Guid negative	
	m cell mutagenicity pected of causing geneti	c dei	ects.	
Con	nponents:			
Tem	nozolomide:			
Gen	notoxicity in vitro	:	Test Type: Bacte Result: positive	rial reverse mutation assay (AMES)
			Test Type: Chror Test system: Hur Result: positive	nosome aberration test in vitro nan lymphocytes
	m cell mutagenicity- As- sment	:		om in vitro mammalian mutagenicity assays, e activity relationship to known germ cell
(+)-	Tartaric acid:			
	notoxicity in vitro	:	Result: negative	rial reverse mutation assay (AMES) on data from similar materials
			Test Type: Chror Result: negative	nosome aberration test in vitro



Temozolomide Formulation

ersion 4	Revision Date: 28.09.2024		S Number: 71311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
			Remarks: Based	on data from similar materials		
				damage and repair, unscheduled DNA syn- Ilian cells (in vitro)		
Genotoxicity in vivo		:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative			
Carci	nogenicity					
Suspe	ected of causing cance	r.				
Comp	oonents:					
Temo	zolomide:					
Speci		:	Rat			
	ation Route	:	Oral 6 Months			
Expos	sure time		6 Months 4 mg/kg body we	aiaht		
Resul	t	:	positive			
Targe	t Organs	:	Mammary gland			
Carcir ment	Carcinogenicity - Assess- ment		Limited evidence of carcinogenicity in animal studies			
Repro	oductive toxicity					
May d	lamage fertility. May da	amage	e the unborn child			
<u>Comp</u>	oonents:					
Temo	zolomide:					
Effect	s on fertility	:	Species: Rat, ma Application Rout			
Effect	s on foetal develop-	:	Test Type: Embr	yo-foetal development		
ment	· · · · · · · · · ·		Species: Rat			
				e: Oral xicity: LOAEL: 13 mg/kg body weight Malformations were observed.		
Repro sessm	oductive toxicity - As- nent	:	ity, based on ani	f adverse effects on sexual function and fert mal experiments., Clear evidence of adverse opment, based on animal experiments.		
(+)-Ta	rtaric acid:					
	s on foetal develop-	:	Test Type: Embr Species: Rat	yo-foetal development		

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371311-00009	Date of first issue: 27.08.2021

Application Route: Ingestion Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Temozolomide:

Exposure routes	: Ingestion
Target Organs	: Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Temozolomide: Species NOAEL LOAEL Application Route Exposure time Target Organs	Rat, female 4 mg/kg 21 mg/kg Oral 6 Months Lymph nodes, thymus gland, Bone marrow, Reproductive organs
Species NOAEL LOAEL Application Route Exposure time Target Organs	Rat, male 8.5 mg/kg 34 mg/kg Oral 6 Months Lymph nodes, thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract
Species NOAEL LOAEL Application Route Exposure time Target Organs	Dog 2.5 mg/kg 6.3 mg/kg Oral 6 Months Bone marrow, spleen, male reproductive organs, Gastrointes- tinal tract, thymus gland
(+)-Tartaric acid: Species NOAEL Application Route Exposure time	Rat > 100 mg/kg Ingestion 2 yr

Version

plants

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

SDS Number:



Date of last issue: 06.04.2024

Temozolomide Formulation

Revision Date:

4.4	28.09.2024		71311-00009	Date of first issue: 27.08.2021				
-	iration toxicity classified based on availa	able	information.					
Exp	Experience with human exposure							
<u>Con</u>	ponents:							
Tem	ozolomide:							
Inge	stion	:	Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss					
SECTIO	N 12: Ecological infor	rma	tion					
12.1 Tox	icity							
Con	ponents:							
Tem	ozolomide:							
Toxi	city to fish	:	Exposure time: 9	chus mykiss (rainbow trout)): > 100 mg/l 6 h rest Guideline 203				
	city to daphnia and other atic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202					
Toxi plan	city to algae/aquatic ts	:	 EC50 (Pseudokirchneriella subcapitata (green algae)): > 9 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 					
			mg/l Exposure time: 7	rchneriella subcapitata (green algae)): 40 2 h est Guideline 201				
Toxi	city to microorganisms	:	EC50 : > 100 mg Exposure time: 3 Test Type: Respi Method: OECD T	h				
(+)-1	Fartaric acid:							
	city to fish	:	LC50 (Danio rerio Exposure time: 9	o (zebra fish)): > 100 mg/l 6 h				

Toxicity to daphnia and other
aquatic invertebrates:EC50 (Daphnia magna (Water flea)): 93.313 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202Toxicity to algae/aquatic:EC50 (Pseudokirchneriella subcapitata (green algae)): 51.404

mg/l

Method: OECD Test Guideline 203

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		DS Number: 71311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
			Exposure time: 7 Method: OECD 1	2 h ⁻ est Guideline 201
			mg/l Exposure time: 7	irchneriella subcapitata (green algae)): 3.125 2 h ēst Guideline 201
Toxic	ity to microorganisms	:	EC50 : > 1,000 n Exposure time: 3 Method: OECD 1	
12.2 Persi	stence and degradab	ility		
Comp	oonents:			
Temo	zolomide:			
Biode	gradability	:	Result: rapidly de Biodegradation: Exposure time: 3	83 %
Stabil	ity in water	:	Degradation half	life (DT50): < 1 d
(+)-Ta	artaric acid:			
Biode	gradability	:	Biodegradation: Exposure time: 2	85 %
12.3 Bioad	ccumulative potential			
<u>Com</u>	oonents:			
Partiti	zolomide: on coefficient: n- ol/water	:	log Pow: 1.35	
Partiti	artaric acid: on coefficient: n- ol/water	:	log Pow: -1.91	
12.4 Mobi	lity in soil			
No da	ata available			
12.5 Resu	Its of PBT and vPvB a	asse	ssment	
Produ	uct:			

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Temozolomide Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
4.4		9371311-00009	Date of first issue: 27.08.2021
12.6 Other	adverse effects		

Product:

Endocrine disrupting poten-		This substance/mixture does not contain components consid- ered to have endocrine disrupting properties for environment
		according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste are not product specific, but application specific. Waste codes should be assigned by the user, prefer discussion with the waste disposal authorities. Do not dispose of waste into sewer.	
Contaminated packaging	Empty containers should be taken to an approved wa dling site for recycling or disposal. If not otherwise specified: Dispose of as unused proc	

SECTION 14: Transport information

14.1 UN number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		

14.4 Packing group

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		DS Number: 371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
ADN		:	Not regulated as	a dangerous good		
ADR		:	Not regulated as	a dangerous good		
RID		:	Not regulated as	a dangerous good		
IMDG	IMDG		: Not regulated as a dangerous good			
IATA (Cargo)		:	Not regulated as a dangerous good			
IATA (Passenger)		:	Not regulated as a dangerous good			
14.5 Environmental hazards Not regulated as a dangerous		s go	od			
	al precautions for use	er				
14.7 Transport in bulk according to Annex II of Marpol and the IBC Code						
Remai	rks	:	Not applicable for	r product as supplied.		
SECTION	SECTION 15: Regulatory information					

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable	
UK REACH Candidate list of su concern (SVHC) for Authorisation	, .	:	Not applicable	
The Persistent Órganic Pollutar Regulation (EU) 2019/1021 as a	nts Regulations (retained	:	Not applicable	
ain) Regulation (EC) on substances laver	that deplete the ozone	:	Not applicable	
UK REACH List of substances s (Annex XIV)	subject to authorisation	:	Not applicable	
GB Export and import of hazard Informed Consent (PIC) Regula		:	Not applicable	
Control of Major Accident Haza	rds Regulations 2015 (CO	MA	H)	
			Quantity 1	Quantity 2
H2	ACUTE TOXIC		50 t	200 t

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.



Temozolomide Formulation

Version 4.4	Revision Date: 28.09.2024		DS Number: 371311-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
The components of this product AICS : DSL :			ct are reported in not determined not determined	the following inventories:	
IECSC :		not determined			
15.2 Chemical safety assessment A Chemical Safety Assessment has not been carried out.					
SECTION 16: Other information					
Other	information	:		nges have been made to the previous version the body of this document by two vertical	

Full text of H-Statements

H300 H318 H341 H351 H360FD H372	::	Fatal if swallowed. Causes serious eye damage. Suspected of causing genetic defects. Suspected of causing cancer. May damage fertility. May damage the unborn child. Causes damage to organs through prolonged or repeated
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox. Carc. Eye Dam. Muta. Repr. STOT RE GB EH40	::	Acute toxicity Carcinogenicity Serious eye damage Germ cell mutagenicity Reproductive toxicity Specific target organ toxicity - repeated exposure UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	:	Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test popula-



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371311-00009	Date of first issue: 27.08.2021

tion; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mix	Classification procedure:	
Acute Tox. 2	H300	Calculation method
Eye Irrit. 2	H319	Calculation method
Muta. 2	H341	Calculation method
Carc. 2	H351	Calculation method
Repr. 1B	H360FD	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN